The Democratic sweep in the November 2026 midterms has sharply reduced prospects for Senate confirmation of Heidi Overton as FDA commissioner during the current lame-duck session. Nominated in August after Martin Makary’s resignation, Overton—a White House domestic policy adviser—testified before the Republican-led Senate HELP Committee in September but has not advanced to a committee vote. Cross-partisan concerns over her positions on vaccine policy, mifepristone safety reviews, and alignment with administration priorities have surfaced from both Democrats and some Republicans, narrowing the confirmation window before Democrats assume control in January. The administration continues to press senators for support, while reports indicate consideration of acting leadership alternatives such as Sara Brenner to maintain agency continuity.